Skip to Content
Merck
All Photos(1)

Documents

SML3967

Sigma-Aldrich

Levonorgestrel

≥98% (HPLC)

Synonym(s):

(17α)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one, 13-Ethyl-17-ethynyl-17β-hydroxy-4-gonen-3-one, 13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one, D(−)-Norgestrel, D-Norgestrel, LNG

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H28O2
CAS Number:
797-63-7
Molecular Weight:
312.45
MDL number:
MFCD01546387
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -28 to -36° (C= 1.0g/100 ml in CDCl3)

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus.

Levonorgestrel (D-Norgestrel) is an orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus. Levonorgestrel inhibits the release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). D(−)-Norgestrel prevents fertilization by altering cervical mucus consistency, and interfering with the endometrial lining, making it less receptive to implantation. Levonorgestrel (LNG) can be used alone or in combination with estrogen during hormone replacement therapy.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H351,H360D,H362

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ioannis D Gallos et al.
American journal of obstetrics and gynecology, 203(6), 547-547 (2010-10-12)
To conduct a systematic review and metaanalysis of studies evaluating the regression rate of endometrial hyperplasia with oral progestogens and levonorgestrel-releasing intrauterine system. Searches were conducted on Medline, Embase, Cochrane Library, and Web of Science, and reference lists of relevant
K Fotherby
Contraception, 54(2), 59-69 (1996-08-01)
The concept of bioavailability is discussed with particular references to the sex steroids. Problems encountered in the measurement of bioavailability of these steroids and the various factors that may affect their bioavailability are briefly described. Information regarding the bioavailability of
Raymond Hang Wun Li et al.
Lancet (London, England), 402(10405), 851-858 (2023-08-20)
Levonorgestrel, a standard drug for emergency contraception (EC), is not effective if administered post-ovulation. A cyclo-oxygenase inhibitor could contribute synergistic effects. We investigated whether a single 40 mg oral dose of piroxicam as co-treatment with levonorgestrel improved emergency contraceptive efficacy.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service